Here, we investigated the diagnostic accuracy of selected tumor biomarkers (i.e., AFP, PIVKA-II and GPC-3); adipokines (i.e., adiponectin and leptin) and IL-6, alone or in combination, for the discrimination between patients with or without NAFLD-related HCC. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.